ACOG Stock Alpha Cognition Inc. Common Stock
STRONG BUY US · NasdaqCMSales ramp plus insider accumulation make this a high-upside, event-driven biotech name.
Future value: $18.00 (+116.87%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Insider buying and Zunveyl commercial ramp.
- ▾Below 50-day MA (-7.07%)
- ▸Above 200-day MA — long-term uptrend
- ▸~117% upside to price target
Is ACOG a buy right now?
Trend: ACOG is trading below the 50-day average (-7.05%), RSI 64 — neutral momentum, with a 3-month return of -1.31%.
Valuation & quality: Alpha Cognition Inc. Common Stock trades on forward P/E -13.4, price-to-book 3.41; fundamentals show net margin -137.7%, return on equity -49.5%, revenue growth 267.6% year on year.
Analyst consensus: 5 analysts have a mean 12-month price target of $18.00 (+116.9% vs the last close; range $12.00 – $21.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Sales ramp plus insider accumulation make this a high-upside, event-driven biotech name.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -8.50% | +8.70% | +3.70% | +16.60% | +14.70% | +12.00% | -2.90% | -7.80% |
Fundamentals
Analyst price target
Technical signals
About Alpha Cognition Inc. Common Stock
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Sector: Healthcare · Industry: Biotechnology · United States · 71 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.